Search Results

There are 437879 results for: content related to: A prospective study of 86 new patients with social anxiety disorder

  1. You have free access to this content
    Paroxetine versus other anti-depressive agents for depression

    Intervention Review

    The Cochrane Library

    Marianna Purgato, Davide Papola, Chiara Gastaldon, Carlotta Trespidi, Laura R Magni, Carla Rizzo, Toshi A Furukawa, Norio Watanabe, Andrea Cipriani and Corrado Barbui

    Published Online : 3 APR 2014, DOI: 10.1002/14651858.CD006531.pub2

  2. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug–drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly

    Pharmacoepidemiology and Drug Safety

    Muh. Akbar Bahar, Eelko Hak, Jens H.J. Bos, Sander D. Borgsteede and Bob Wilffert

    Version of Record online : 26 MAR 2017, DOI: 10.1002/pds.4200

  3. Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies

    Rapid Communications in Mass Spectrometry

    Volume 17, Issue 13, 15 July 2003, Pages: 1455–1461, Mireia Segura, Jordi Ortuño, Magí Farré, Roberta Pacifici, Simona Pichini, Jesús Joglar, Jordi Segura and Rafael de la Torre

    Version of Record online : 22 MAY 2003, DOI: 10.1002/rcm.1067

  4. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 6, November 2014, Pages: 568–577, William A. Ball, Duane B. Snavely, Richard J. Hargreaves, Armin Szegedi, Christopher Lines and Scott A. Reines

    Version of Record online : 20 OCT 2014, DOI: 10.1002/hup.2444

  5. Therapeutic advances: Paroxetine for the treatment of social anxiety disorder

    Depression and Anxiety

    Volume 11, Issue 3, 2000, Pages: 99–104, R. Bruce Lydiard and Julio Bobes

    Version of Record online : 17 MAY 2000, DOI: 10.1002/(SICI)1520-6394(2000)11:3<99::AID-DA3>3.0.CO;2-Z

  6. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo

    Human Psychopharmacology: Clinical and Experimental

    Volume 26, Issue 1, January 2011, Pages: 72–76, Sara I. J. Schutters, Harold J. G. M. van Megen, J. Frederieke Van Veen, Koen R. J. Schruers and Herman G. M. Westenberg

    Version of Record online : 9 FEB 2011, DOI: 10.1002/hup.1165

  7. You have free access to this content
    Paroxetine: A Review

    CNS Drug Reviews

    Volume 7, Issue 1, March 2001, Pages: 25–47, Michel Bourin, Pierre Chue and Yannick Guillon

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2001.tb00189.x

  8. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies

    Birth Defects Research Part A: Clinical and Molecular Teratology

    Volume 88, Issue 3, March 2010, Pages: 159–170, Keele E. Wurst, Charles Poole, Sara A. Ephross and Andrew F. Olshan

    Version of Record online : 8 SEP 2009, DOI: 10.1002/bdra.20627

  9. A phase I open-label study to investigate the potential drug–drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers

    The Journal of Clinical Pharmacology

    Volume 54, Issue 5, May 2014, Pages: 555–562, Ana Ruiz-Garcia, Nagdeep Giri, Robert R. LaBadie, Grace Ni, Tanya Boutros, Nicole Richie, Hetal S. Kocinsky, Tina M. Checchio and Carlo L. Bello

    Version of Record online : 17 DEC 2013, DOI: 10.1002/jcph.243

  10. Persistent benefits of slow titration of paroxetine in a six-month follow-up

    Human Psychopharmacology: Clinical and Experimental

    Volume 30, Issue 5, September 2015, Pages: 329–333, Paolo Olgiati and Alessandro Serretti

    Version of Record online : 21 APR 2015, DOI: 10.1002/hup.2478

  11. Association between plasma paroxetine concentration and changes in plasma brain-derived neurotrophic factor levels in patients with major depressive disorder

    Human Psychopharmacology: Clinical and Experimental

    Volume 26, Issue 3, April 2011, Pages: 194–200, Norio Yasui-Furukori, Shoko Tsuchimine, Taku Nakagami, Akira Fujii, Yasushi Sato, Tetsu Tomita, Kaori Yoshizawa, Yoshimasa Inoue and Sunao Kaneko

    Version of Record online : 3 JUN 2011, DOI: 10.1002/hup.1192

  12. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 37, Issue 3, March 2017, Pages: 287–296, Vishal Bali, Satabdi Chatterjee, Michael L. Johnson, Hua Chen, Ryan M. Carnahan and Rajender R. Aparasu

    Version of Record online : 22 FEB 2017, DOI: 10.1002/phar.1898

  13. You have free access to this content
    Effects of chronic paroxetine treatment on dialysate serotonin in 5-HT1B receptor knockout mice

    Journal of Neurochemistry

    Volume 86, Issue 1, July 2003, Pages: 13–24, A. M. Gardier, D. J. David, G. Jego, C. Przybylski, C. Jacquot, S. Durier, B. Gruwez, E. Douvier, P. Beauverie, N. Poisson, R. Hen and M. Bourin

    Version of Record online : 4 FEB 2004, DOI: 10.1046/j.1471-4159.2003.01827.x

  14. Paroxetine in social anxiety disorder: a randomized placebo-controlled study

    Acta Psychiatrica Scandinavica

    Volume 100, Issue 3, September 1999, Pages: 193–198, C. Allgulander

    Version of Record online : 13 NOV 2007, DOI: 10.1111/j.1600-0447.1999.tb10845.x

  15. A Complex Relationship Between Co-occurring Social Anxiety and Alcohol Use Disorders: What Effect Does Treating Social Anxiety Have on Drinking?

    Alcoholism: Clinical and Experimental Research

    Volume 32, Issue 1, January 2008, Pages: 77–84, Suzanne E. Thomas, Patrick K. Randall, Sarah W. Book and Carrie L. Randall

    Version of Record online : 20 NOV 2007, DOI: 10.1111/j.1530-0277.2007.00546.x

  16. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

    Human Psychopharmacology: Clinical and Experimental

    Volume 19, Issue 6, August 2004, Pages: 387–396, Christer Allgulander, Richard Mangano, Jun Zhang, Alv A. Dahl, Ulla Lepola, Ingemar Sjödin and Gerard Emilien

    Version of Record online : 15 JUN 2004, DOI: 10.1002/hup.602

  17. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients

    Depression and Anxiety

    Volume 14, Issue 4, 2001, Pages: 255–262, Carrie L. Randall, Michael R. Johnson, Angelica K. Thevos, Susan C. Sonne, Suzanne E. Thomas, Shauna L. Willard, Kathleen T. Brady and Jonathan R. Davidson, M.D.

    Version of Record online : 29 NOV 2001, DOI: 10.1002/da.1077

  18. You have free access to this content
    Pharmacotherapy for anxiety and comorbid alcohol use disorders

    Intervention Review

    The Cochrane Library

    Jonathan C Ipser, Don Wilson, Taiwo O Akindipe, Carli Sager and Dan J Stein

    Published Online : 20 JAN 2015, DOI: 10.1002/14651858.CD007505.pub2

  19. Therapeutic Armamentarium in Anxiety Disorders

    Biological Psychiatry

    J. A. den Boer, B. R. Slaap, G. J. ter Horst, T. I. F. H. Cremers, F. J. Bosker, Pages: 1039–1062, 2003

    Published Online : 26 SEP 2003, DOI: 10.1002/0470854871.chxix13

  20. Selective Serotonin Reuptake Inhibitors in the Treatment of the Anxiety Disorders

    Anxiety Disorders

    D.J. Nutt, J.C. Ballenger, Pages: 339–361, 2007

    Published Online : 26 OCT 2007, DOI: 10.1002/9780470986844.ch18